



## Behavioral Health Standing Committee Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

### *Measures Under Review (Phase 4) & Committee Member Recusals*

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
0004	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"><li>• <b>Constance Horgan, ScD</b> Professor and Director, Institute of Behavioral Health, the Heller School for Social Policy and Management, Brandeis University</li><li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li></ul>
0027	Medical Assistance with Smoking and Tobacco Use Cessation (MSC)	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"><li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li></ul>



0108	Follow-Up Care for Children Prescribed ADHD Medication (ADD)	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"> <li>• <b>Constance Horgan, ScD</b> Professor and Director, Institute of Behavioral Health, the Heller School for Social Policy and Management, Brandeis University</li> <li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li> </ul>
0576	Follow-Up After Hospitalization for Mental Illness (FUH)	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"> <li>• <b>Constance Horgan, ScD</b> Professor and Director, Institute of Behavioral Health, the Heller School for Social Policy and Management, Brandeis University</li> <li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li> </ul>
1937	Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"> <li>• <b>Constance Horgan, ScD</b> Professor and Director, Institute of Behavioral Health, the Heller School for Social Policy and Management, Brandeis University</li> <li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li> </ul>



2600	Tobacco Use Screening and Follow-up for People with Serious Mental Illness or Alcohol or Other Drug Dependence	National Committee for Quality Assurance (NCQA)	<ul style="list-style-type: none"> <li>• <b>Constance Horgan, ScD</b> Professor and Director, Institute of Behavioral Health, the Heller School for Social Policy and Management, Brandeis University</li> <li>• <b>Harold Pincus, MD</b> Director of Quality and Outcomes Research, New York-Presbyterian Hospital, The University Hospital of Columbia and Cornell</li> </ul>
3132	Preventive Care and Screening- Screening for Depression and Follow-Up Plan	Centers for Medicare & Medicaid Services (CMS)	<ul style="list-style-type: none"> <li>• <b>Michael Trangle, MD</b> Senior Medical Director, Behavioral Health Division, HealthPartners Medical Group, Regions Hospital</li> </ul>
3148	Preventive Care and Screening- Screening for Clinical Depression and Follow-Up Plan	Centers for Medicare & Medicaid Services (CMS)	<ul style="list-style-type: none"> <li>• <b>Michael Trangle, MD</b> Senior Medical Director, Behavioral Health Division, HealthPartners Medical Group, Regions Hospital</li> </ul>
3172	Continuity of Pharmacotherapy for Alcohol Use Disorder	RAND Corporation	<ul style="list-style-type: none"> <li>• <b>Mady Chalk, PhD, MSW</b> Senior Policy Advisor, Treatment Research Institute</li> </ul>
3175	Continuity of Pharmacotherapy for Opioid Use Disorder	RAND Corporation	<ul style="list-style-type: none"> <li>• <b>Mady Chalk, PhD, MSW</b> Senior Policy Advisor, Treatment Research Institute</li> </ul>
3205	Medication Continuation Following Inpatient Psychiatric Discharge	Centers for Medicare & Medicaid Services (CMS), Contracting Officer's Representative (COR)	<ul style="list-style-type: none"> <li>• <b>Lisa Shea, MD, DFAPA</b> Medical Director, Butler Hospital, System Medical Director for Medical Staff Credentialing, Care New England Health System</li> </ul>



3207	Medication Reconciliation on Admission	Centers for Medicare & Medicaid Services (CMS), Contracting Officer's Representative (COR)	<ul style="list-style-type: none"><li>• <b>Lisa Shea, MD, DFAPA</b> Medical Director, Butler Hospital, System Medical Director for Medical Staff Credentialing, Care New England Health System</li></ul>
3229	Patient Panel Adult Smoking Prevalence	Centers for Medicare & Medicaid Services (CMS)	<ul style="list-style-type: none"><li>• <b>Peter Briss, MD, MPH</b> Medical Director, Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion</li></ul>